In his calm and understated way, Dr. Martin Metz moves between two worlds that often barely touch: One is filled with white coats, data, and the quiet rhythm of life in the lab; the other with the unpredictability of patients, their pain, relief, and stories. Metz lives at the junction of these two medical highways, a physician and scientist whose work has helped redefine how we understand mast-cell-driven diseases like urticaria. https://lnkd.in/eCVqnB57 #NovartisLive
About us
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
- Website
-
http://www.novartis.com
External link for Novartis
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Basel, Baselstadt
- Type
- Public Company
- Specialties
- Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand, and Gene and cell therapy
Locations
Employees at Novartis
Updates
-
At Novartis, we advance bold science to help bring relief and renewed hope to people living with immune-mediated diseases. Our presence at #EAACI2026 reflects our focus on diseases with limited treatment options. No one can reimagine medicine alone. That’s why we partner with patients, physicians and healthcare systems to drive meaningful progress. Together, we are shaping what’s next in Immunology to help people live better, not just longer. 📍Discover what’s next in Immunology at European Academy of Allergy and Clinical Immunology - EAACI
-
-
Our legacy in hematology runs deep, shaped by a commitment to keep asking questions, challenging norms and striving for better answers in a uniquely complex field. With #EHA2026 around the corner, we continue to push forward the science and innovation shaping the future of hematology care. Learn more: https://lnkd.in/eGh8Tfn5
-
Kidney disease is not always loud. IgA nephropathy (IgAN) can progress quietly for years, involving different immune‑system processes and often discovered only after kidney damage has begun. Understanding what causes IgAN, why early recognition matters, and why treatment approaches are evolving is key to better conversations and better care. Read our latest article ahead of ERA. 👇 #ProtectingKidneyTransformingCare #KidneyDisease #IgAN #IgANephropathy #EarlyDiagnosis
-
A healthier planet supports healthier lives. We have been recognized for our climate leadership in the Financial Times Europe Climate Leaders and Newsweek World’s Greenest Companies. Behind the rankings are the colleagues who work each day to advance sustainability across Novartis. Swipe to find out more about them.
-
Decades of leadership in chronic myeloid leukemia (CML) continue to shape what comes next, with new long term CML data from Novartis presented at the 2026 ASCO® Annual Meeting. We are partnering with patient organizations like CML Advocates Network, with the commitment to deliver lasting impact for people living with CML. #ReimaginingOncology #ASCO26 #WeGoFurther #NovartisOncology
-
Progressive kidney diseases continue to place a significant burden on patients worldwide—often advancing quietly over time. At Novartis, we are committed to leading the transformation of kidney care by advancing science, deepening understanding of disease, and taking a long‑term approach to improving outcomes for people living with serious kidney conditions. As the global kidney community comes together ahead of the European Renal Association (ERA) Congress, our focus remains clear: protecting kidney health today while helping to shape the future of care. #ProtectingKidneysTransformingCare #KidneyDisease #IgAN #IgANephropathy #ERA26
-
Innovation in oncology is everywhere, but turning breakthroughs into impact? That’s the real work. At the 2026 ASCO® Annual Meeting, our US and International team members tackled a bigger question: How do we move cancer care forward in a way that can actually reach patients? 🎬 Learn how our leaders are thinking differently so bold science can reach more patients.
Through Our Eyes
-
In oncology, what comes next matters as much as what comes first. As pioneers in radioligand therapy (RLT), we continue to innovate in prostate cancer. At 2026 ASCO® Annual Meeting, an oral presentation will feature new data advancing treatment options in metastatic disease. #ReimaginingOncology #ASCO26 #WeGoFirst #NovartisOncology
-
Real impact isn’t always loud or obvious. Often, it’s choosing to show up, especially when it’s hard. As we celebrate Pride Month at Novartis, Korab Zuka, Global Head of Social Impact & Chief Sustainability Officer shares his story – what it means to be visible, to keep going, and to support others along the way. Because inclusion isn’t built in one moment. It’s built in the everyday, conscious actions we all make. That’s how cultures change and evolve. That’s how people thrive. At Novartis, we believe impact starts with us. Watch Korab’s story and join us in showing up during Pride Month and beyond. #Pride2026 #CollectiveCommitment #Thrivetogether